- Home
- OGI vs LYEL Comparison
OGI vs LYEL Comparison
Compare OGI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- LYEL
- Stock Information
- Founded
- OGI 2013
- LYEL 2018
- Country
- OGI Canada
- LYEL United States
- Employees
- OGI N/A
- LYEL N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- OGI Health Care
- LYEL Health Care
- Exchange
- OGI Nasdaq
- LYEL Nasdaq
- Market Cap
- OGI 170.2M
- LYEL 203.9M
- IPO Year
- OGI N/A
- LYEL 2021
- Fundamental
- Price
- OGI $1.31
- LYEL $0.70
- Analyst Decision
- OGI
- LYEL Sell
- Analyst Count
- OGI 0
- LYEL 2
- Target Price
- OGI N/A
- LYEL $1.00
- AVG Volume (30 Days)
- OGI 1.3M
- LYEL 1.3M
- Earning Date
- OGI 02-11-2025
- LYEL 03-03-2025
- Dividend Yield
- OGI N/A
- LYEL N/A
- EPS Growth
- OGI N/A
- LYEL N/A
- EPS
- OGI N/A
- LYEL N/A
- Revenue
- OGI $115,451,336.00
- LYEL $63,000.00
- Revenue This Year
- OGI $50.11
- LYEL N/A
- Revenue Next Year
- OGI $16.16
- LYEL N/A
- P/E Ratio
- OGI N/A
- LYEL N/A
- Revenue Growth
- OGI N/A
- LYEL N/A
- 52 Week Low
- OGI $1.24
- LYEL $0.51
- 52 Week High
- OGI $2.91
- LYEL $3.26
- Technical
- Relative Strength Index (RSI)
- OGI 38.71
- LYEL 64.48
- Support Level
- OGI $1.27
- LYEL $0.57
- Resistance Level
- OGI $1.38
- LYEL $0.63
- Average True Range (ATR)
- OGI 0.10
- LYEL 0.05
- MACD
- OGI -0.03
- LYEL 0.02
- Stochastic Oscillator
- OGI 14.00
- LYEL 87.86
About OGI Organigram Holdings Inc.
OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds brands, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.